Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
-
REGULATORY DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
-
ORGANIZATION Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
-
REGULATORY Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
-
REGULATORY DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
-
BUSINESS Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
-
ORGANIZATION Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
-
BUSINESS MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
-
REGULATORY LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
-
BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
-
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
-
REGULATORY Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
-
REGULATORY Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
-
BUSINESS Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
-
REGULATORY DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
-
ORGANIZATION Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
-
BUSINESS Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
-
REGULATORY Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
-
COMMENTARY With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…